Pancreatic cancer trials in China

In China 326 Also abroad 1095

326 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Beijing, Chengdu, Guangzhou, Shanghai
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
No phaseNot yet taking people in China
A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer
Where
Chengdu, Qingdao, Shanghai, Xi'an
Age
18 years to 75 years
People
56
Run by
Ruijin Hospital
See details and how to joinNCT07928362
Phase 1/2Taking people
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC
Where
Chengdu
Age
18 years to 75 years
People
45
Run by
West China Hospital
See details and how to joinNCT07802184
No phaseTaking people
Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer Lesions
Where
Shanghai
Age
18 years to 75 years
People
50
Run by
Ruijin Hospital
See details and how to joinNCT07925125
Phase 2Enrolling by invitation
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Where
Shanghai
Age
18 years to 75 years
People
45
Run by
Fudan University
See details and how to joinNCT07920731
Phase 1Taking people
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Where
Changsha
Age
18 years and over
People
540 worldwide
Run by
Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00
No phaseNot yet taking people in China
AI-Assisted Differentiation of Pancreatic Cystic Lesions Using EUS Images and Clinical Features
Where
Shanghai
Age
18 years and over
People
400
Run by
Ruijin Hospital
See details and how to joinNCT07919704
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Beijing, Guangzhou, Shanghai
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Beijing, Changsha, Hangzhou, Shanghai
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 1Taking people
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Shanghai
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Beijing, Chongqing, Guangzhou, Shanghai, Xinxiang
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 1/2Taking people
A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
Where
Beijing
Age
18 years to 75 years
People
52
Run by
Beijing Gene Key Life Technology Co., Ltd
See details and how to joinNCT07777211
Phase 3Taking people
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Where
Guangzhou, Shanghai
Age
18 years and over
People
614 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07409272 · EU 2025-523684-38-00
Phase 2/3Taking people
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Where
Hong Kong
Age
18 years and over
People
440 worldwide
Run by
Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00
Phase 1/2Taking people
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Where
Beijing, Changsha, Chengdu, Fuzhou, Shanghai, Wuhan
Age
18 years and over
People
220 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06428409 · EU 2023-508703-21-00
Phase 1/2Taking people
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Where
Beijing, Hangzhou, Nanjing, Wuhan
Age
18 years and over
People
450 worldwide
Run by
Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00
Phase 3Not yet taking people in China
HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer
Where
Beijing, Shanghai
Age
18 years to 75 years
People
825
Run by
Shanghai Hengrui Pharmaceutical Co., Ltd.
See details and how to joinNCT07900789
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Chengdu, Guangzhou
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 3Taking people
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer
Where
Shanghai
Age
18 years to 75 years
People
588
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07232875
Phase 1/2Taking people
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors
Where
Shanghai
Age
18 years to 70 years
People
140
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07806058
No phaseTaking people
Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy
Where
Ningbo
Age
18 years to 85 years
People
27
Run by
Ningbo Medical Center Lihuili Hospital
See details and how to joinNCT07892573
Phase 1Taking people
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
Where
Beijing, Changsha, Hangzhou, Shanghai, Wuhan, Xian, Zhengzhou
Age
18 years to 79 years
People
20
Run by
CARsgen Therapeutics Co., Ltd.
See details and how to joinNCT05911217
Phase 2Taking people
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Where
Jinan
Age
18 years to 75 years
People
25
Run by
Shandong Cancer Hospital and Institute
See details and how to joinNCT06050317
No phaseTaking people
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
Where
Beijing
Age
18 years and over
People
50
Run by
Peking University Third Hospital
See details and how to joinNCT07760012
Phase 2Not yet taking people in China
Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
Where
Hangzhou
Age
18 years and over
People
120
Run by
Bing Xia
See details and how to joinNCT07875465